Related Experiment Video
Updated: Jul 30, 2026
06:32
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae
G M Bahr1, M A Shaaban, M Gabriel
1Department of Microbiology, Faculty of Medicine, Kuwait University, Safat.
Tubercle
|December 1, 1990
Summary
Investigating immunotherapeutic injections for tuberculosis, researchers found that modified M. vaccae preparations significantly increased immune responses. The most effective involved higher doses or autoclaved M. vaccae, enhancing lymphocyte proliferation and antibody production.
Area of Science:
- Immunology
- Microbiology
- Pulmonary Medicine
Background:
- Previous studies showed irradiation-killed Mycobacterium vaccae injections alter immune responses to mycobacterial antigens in tuberculosis patients.
- A single dose of 10(9) M. vaccae increased antigen-responsive lymphocytes compared to saline placebo.
Purpose of the Study:
- To optimize the immunotherapeutic potential of M. vaccae injections by assessing six modifications.
- To enhance lymphocyte proliferation and antibody responses to mycobacterial antigens in tuberculosis patients.
Main Methods:
- Six modified M. vaccae injection formulations were randomized against saline placebo.
- Efficacy was assessed using biochemical, clinical, hematological, immunological, and radiological criteria.
- Lymphocyte proliferation assays and antibody subclass responses were measured post-injection.
Main Results:
- Modified M. vaccae injections significantly increased lymphocyte proliferation to mycobacterial antigens.
- The most effective formulations included Tuberculin plus murabutide plus 10(9) M. vaccae, autoclaved 10(9) M. vaccae, and 2 x 10(9) irradiated M. vaccae.
- Antibody responses (IgG subclasses) to mycobacteria increased, with no change in streptococcal responses.
- Radiological assessment indicated delayed consolidation clearing but improved cavity closure with autoclaved M. vaccae.
Conclusions:
- Specific modifications of M. vaccae injections, particularly higher doses or autoclaved preparations, enhance immune responses in tuberculosis patients.
- These modifications show potential for improved immunotherapeutic strategies against tuberculosis.
- Further research is warranted to explore the clinical utility of optimized M. vaccae formulations.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis II
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:23Tuberculosis
Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...